Who Are We?
Carmine Therapeutics, a Boston-Singapore Esco Ventures X company, is pioneering a powerful new class of medicines based on red blood cell extracellular vesicles (RBCEVs), for the delivery of novel therapeutic modalities that include nucleic acids.
Red blood cell extracellular vesicles
RBCEVs are safe as they are produced by RBCs physiologically. RBCs naturally lack genetic material, making RBCEVs biocompatible and non-immunogenic
Large quantities of RBCEVs can be obtained from a single unit of blood, bypassing the need for culture expansion of cell source
RBCEVs are highly amenable to manipulations such as cargo loading and surface modification
Powering genetic medicines
Using Red blood cell extracellular vesicles, we are developing a non-viral , in vivo, re-dosable gene therapy, overcoming current limitations of viral based gene therapies like immunogenicity, small transgene capacity and manufacturing challenges.
Prof. Harvey Lodish
Professor Lodish is a Founding Member of the Whitehead Institute for Biomedical Research and Professor of Biology and Professor of Biological Engineering at the Massachusetts Institute of Technology. To date, his group has made key discoveries in the fields of red blood cell development and therapeutics, long non-coding RNAs and adipocyte biology.
Dr. Minh Le
Dr. Minh Le is well recognised for her contributions to the field of microRNAs, extracellular vesicles and cancer biology. Her group at the City University of Hong Kong focuses on the functions of extracellular vesicles in cancer microenvironment and applications of red blood cell extracellular vesicles in anti-cancer therapies.
Dr. Jiahai Shi
Dr. Shi's research interest lies in investigating important aspects of red blood cell (RBC) development, as well as utilizing RBCs for bioengineering. He discovered a new mechanism for alternative pre-mRNA splicing in RBC development and also co-invented a new technology for engineering RBCs as carriers for a wide range of therapeutic cargoes.
XQ is the Founder and Managing Partner of Esco Ventures, the corporate venture and incubation arm of Esco Group.
Tenzin Gocha, PhD
Director, Scientific and Business Operations
Tenzin obtained his PhD in Molecular Pharmacology from New York University Medical Center.
Ronne Yeo, PhD
Ronne spent 3 years performing basic research on extracellular vesicles (EVs) and accumulated an additional 4 years of pre-clinical discovery and development experience working on an EV-based biotech spin-off from A*STAR Singapore.
Elan Ezickson brings extensive biopharmaceutical operational, strategic and capital formation expertise to Carmine's board, most recently having served as the Chief Operating Officer and head of corporate development at Scholar Rock Holding Corporation.
700 Main Street, North
Cambridge, MA 02139
21 Biopolis Road Nucleos #02-03/05 Singapore 138567
We are seeking talented scientists in Singapore and Cambridge/Boston to join our team, in order to bring this new therapeutic modality into the clinic and beyond.